Abstract: A duct for the passage of a fluid to be detected and/or measured, for use with an ultrasound device for measuring the fluid includes: first and second pieces entirely or mostly made of polymeric material, configured to be joined and fixed together to define a measuring channel. The first piece includes: a first port for the inlet or outlet of the fluid to be measured; a first opening in the first piece for passage of ultrasonic signals emitted/received by at least one first ultrasonic sensor mounted on the first piece; a first tubular portion provided with a first abutment edge. The second piece includes: a second port for outlet or entry of the fluid from/into the duct; a second opening therein for passage of ultrasonic signals emitted/received by at least one second ultrasonic sensor mounted on the second piece; and a second tubular portion provided with a second abutment edge.

Abstract: A circuit includes a clock input node, a first signal input node configured to receive a first modulated signal switching between a first DC voltage and a second DC voltage, a bias circuit, a first output node, a first capacitor, a second capacitor, and switching circuitry coupled to the first capacitor and the second capacitor. Control circuitry is configured to initially set the switching circuitry in a first configuration in response to the first modulated signal having the second DC voltage, thereby charging the first capacitor to the second DC voltage and charging the second capacitor to the first DC voltage, and subsequently set the switching circuitry in a second configuration in response to an edge detected in the clock signal, thereby producing the first threshold voltage at the first output node after charge redistribution taking place between the first and second capacitors.

Abstract: The present invention relates to substituted 3-amino indazole derivatives as kinase inhibitors and in particular as inhibitors of CDK11 families. Due to the key role of protein kinases, in particular of CDK11, in the regulation of cellular proliferation, such compounds are thus useful to treat diseases caused by altered CDK11 activity, in particular in the treatment of cancer as well as in the treatment of a variety of cell proliferative disorders and immune-related disorder. The present invention also provides methods for preparing these compounds, pharmaceutical compositions comprising these compounds, and methods of treating diseases utilizing pharmaceutical compositions comprising these compounds.

Abstract: A system and method for tracking and administering liquid intravenous medications in a hospital, clinic, or patient residence, including recording information onto a short range communication device affixed to a liquid container in a hospital pharmaceutical filling or compounding center, the information including drug information, patient information, and IV administration information, transferring the liquid container to a patient's bedside, programming an infusion course into a bedside IV infusion pump by enabling the pump to read the encoded information on the communication device, and disposing of the liquid container and any residual drug in a smart disposal bin that reads the communication device and weighs the container. The disposal bin may confirm the chemical contents of the container.

Abstract: A duct for the passage of a fluid to be detected/measured, for an ultrasound device includes: first and second pieces configured to be joined and fixed together to define a measurement channel, to be crossed by the fluid to be measured; a first port for the inlet/outlet of the fluid to be measured in/from the duct; and a second port for the outlet or entry of the fluid from/into the duct. The first piece includes a tubular portion with an open/missing area and the second piece is configured to close the first piece that the two pieces define the measurement channel which is closed in a fluid-tight manner in correspondence with the areas of union between the two pieces. The second piece includes an internal area configured to be lapped by the fluid passing through the duct and in which a signal emitted by a sensor is reflected.

Abstract: A medical device communication method that may be implemented within a variety of medical devices including but not limited to infusion pumps. The method may be implemented with a protocol stack for at least intra-device communication. Embodiments provide connection-oriented, connectionless-oriented, broadcast and multicast data exchange with priority handling of data, fragmentation, and reassembly of data, unique static and dynamic address assignment and hot swap capability for connected peripherals or subsystems.

Abstract: N-(2,6-diethylphenyl)-8-({4-[4-(dimethylamino)piperidin-1-yl]-2-methoxyphenyl} amino)-1-methyl-4,5-dihydro-1H-pyrazolo[4,3-h]quinazoline-3-carboxamide phosphate of formula (II): Medicinal products containing the same which are useful in treating cancer, cell proliferative disorders, viral infections, autoimmune and neurodegenerative disorders.

Abstract: A medical device communication method that may be implemented within a variety of medical devices including but not limited to infusion pumps. The method may be implemented with a protocol stack for at least intra-device communication. Embodiments provide connection-oriented, connectionless-oriented, broadcast and multicast data exchange with priority handling of data, fragmentation, and reassembly of data, unique static and dynamic address assignment and hot swap capability for connected peripherals or subsystems.

Abstract: A circuit includes a clock input node, a first signal input node configured to receive a first modulated signal switching between a first DC voltage and a second DC voltage, a bias circuit, a first output node, a first capacitor, a second capacitor, and switching circuitry coupled to the first capacitor and the second capacitor. Control circuitry is configured to initially set the switching circuitry in a first configuration in response to the first modulated signal having the second DC voltage, thereby charging the first capacitor to the second DC voltage and charging the second capacitor to the first DC voltage, and subsequently set the switching circuitry in a second configuration in response to an edge detected in the clock signal, thereby producing the first threshold voltage at the first output node after charge redistribution taking place between the first and second capacitors.

Abstract: In accordance with an embodiment, an envelope detector includes a first transistor having a first current conduction terminal coupled to a first connection node; a second current conduction terminal coupled to an intermediate node; and a control terminal coupled the signal input node and to a biasing node; a second transistor having a first current conduction terminal coupled to the intermediate node; a second current conduction terminal coupled to a second connection node; and a control terminal coupled to the biasing node; and a first temperature compensating transistor that is diode-connected and coupled between a compensation output node and the biasing node. The second connection node is coupled to the compensation output node and the first connection node is coupled to a detector output.

Abstract: A medical device communication method that may be implemented within a variety of medical devices including but not limited to infusion pumps. The method may be implemented with a protocol stack for at least intra-device communication. Embodiments provide connection-oriented, connectionless-oriented, broadcast and multicast data exchange with priority handling of data, fragmentation, and reassembly of data, unique static and dynamic address assignment and hot swap capability for connected peripherals or subsystems.

Abstract: A system and method for tracking and administering liquid intravenous medications in a hospital, clinic, or patient residence, including recording information onto a short range communication device affixed to a liquid container in a hospital pharmaceutical filling or compounding center, the information including drug information, patient information, and IV administration information, transferring the liquid container to a patient's bedside, programming an infusion course into a bedside IV infusion pump by enabling the pump to read the encoded information on the communication device, and disposing of the liquid container and any residual drug in a smart disposal bin that reads the communication device and weighs the container. The disposal bin may confirm the chemical contents of the container.

Abstract: A method of producing a pharmaceutical gel emulsion, wherein the emulsion is an oil-in-water gel emulsion, comprising the steps of forming an oil-in-water emulsion comprising at least one pharmaceutically acceptable oil, at least one aqueous phase, at least one osmotic agent, at least one emulsifying agent, mixing a gelling polysaccharide with the oil-in-water emulsion and allowing the resulting mixture to form the pharmaceutical gel emulsion, optionally mixing an bioactive agent into the pharmaceutical gel emulsion.

Abstract: A medical device communication method that may be implemented within a variety of medical devices including but not limited to infusion pumps. The method may be implemented with a protocol stack for at least intra-device communication. Embodiments provide connection-oriented, connectionless-oriented, broadcast and multicast data exchange with priority handling of data, fragmentation, and reassembly of data, unique static and dynamic address assignment and hot swap capability for connected peripherals or subsystems.

Abstract: Aspects of this disclosure relate to a pump cassette with a radio frequency identification (RFID) tag. The RFID tag can store information associated with the pump cassette, such as usage information and/or a unique identifier. The RFID tag can be embedded in a component of the pump cassette in certain embodiments. Related infusion pumps, infusion sets, and infusion systems are disclosed.

Abstract: Various techniques for facilitating server-initiated transmission of messages to medical devices are described herein. For example, a hospital server may transmit strictly regulated clinical requests or messages to medical devices to facilitate clinical operations performed on the medical devices. In addition, the hospital server may transmit requests or messages that are unregulated (or regulated to a lesser degree) to the medical devices to facilitate operations unrelated to the clinical operations of the medical devices. By allowing both regulated and unregulated communications and by allowing both medical-device-initiated and server-initiated uses of the input and output devices provided on the medical devices, faster response times and increased efficiency can be achieved in a hospital environment.

Abstract: A system configured to reconfigure the settings on a medical device based on a detected location of the medical device is provided. The system may include a server configured to receive a connection request from a medical device, update the settings on the medical device, determine that the medical device has entered another geographical area, and transmit, to the medical device, additional settings that can be used to connect to another server configured to communicate with medical devices in said another geographical area.

Abstract: N-(2,6-diethylphenyl)-8-({4-[4-(dimethylamino)piperidin-1-yl]-2-methoxyphenyl}amino)-1-methyl-4,5-dihydro-1H-pyrazolo[4,3-h]quinazoline-3-carboxamide phosphate of formula (II): Medicinal products containing the same which are useful in treating cancer, cell proliferative disorders, viral infections, autoimmune and neurodegenerative disorders.

Abstract: The object of the present invention relates to the new and surprising use of sulfated hyaluronic acid (HAS) as regulator agent of the cytokine activity (pro- and anti-inflammatory) and consequently the use of HAS for the preparation of a new medicine for topic use in the prevention and treatment of pathologies associated with the activation and/or deficiency of cytokines of a pro- and anti-inflammatory nature. The Applicant has in fact discovered the exclusive capacity of HAS in modulating the activity of these particular proteins, it has studied the action mechanism and demonstrated the substantial difference between the different sulfated types known in the state of the art, but above all it has demonstrated an unexpectedly high activity of HAS vs different types and strains of Herpes virus, Cytomegalovirus and the virus of vesicular stomatitis. Finally, a further object of the present invention is the use of HAS as a skin absorption promoter of drugs of an anti-inflammatory nature.

Abstract: New N-(2,6-diethylphenyl)-8-({4-[4-(dimethyl amino)piperidin-1-yl]-2-methoxyphenyl}amino)-1-methyl-4,5-dihydro-1H-pyrazolo[4,3-h]quinazoline-3-carboxamide phosphate of formula (II): Medicaments.